Product image of Heminevrin (Clomethiazole Edisilate) supplied by GNH India

Heminevrin

Active Ingredient:
Clomethiazole Edisilate
Origin:
EU

Heminevrin (Clomethiazole Edisilate)

Heminevrin is a prescription medication whose active ingredient is clomethiazole edisylate. It is supplied in oral dosage form, though specific strength and formulation details are not publicly disclosed. Classified as a thiazole‑derivative sedative, Heminevrin acts as a positive allosteric modulator of the GABA‑A receptor, enhancing inhibitory neurotransmission in the central nervous system. The product is marketed within the European Union and is available by prescription only.

Manufacturer / TM Owner

Cheplapharm Arzneimittel Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Heminevrin is indicated for several clinical situations where central nervous system depression is required.

  • Management of alcohol withdrawal syndrome
  • Procedural sedation in hospital settings
  • Short‑term treatment of severe insomnia
  • Adjunctive therapy for acute agitation
  • Supportive care in acute stress reactions

Side Effects

Heminevrin may produce a range of side effects, varying from mild to serious.

Common

  • Drowsiness or somnolence
  • Dizziness or light‑headedness
  • Headache
  • Nausea or gastrointestinal discomfort
  • Dry mouth
  • Mild hypotension

Serious

  • Respiratory depression, especially when combined with other depressants
  • Severe hypotension or cardiovascular instability
  • Hepatic dysfunction or elevated liver enzymes
  • Allergic reactions such as rash or angioedema
  • Seizures or paradoxical excitation
  • Profound sedation leading to loss of consciousness

Precautions & Warnings

When prescribing Heminevrin, clinicians should observe several safety considerations.

  • Use only under direct medical supervision and according to approved indications
  • Assess liver function before initiation and monitor periodically
  • Avoid abrupt discontinuation to reduce risk of withdrawal phenomena
  • Exercise caution in elderly patients due to increased sensitivity to sedation
  • Contraindicated in patients with known hypersensitivity to clomethiazole or related compounds
  • Monitor respiratory status in individuals with pre‑existing respiratory compromise
  • Evaluate for potential dependence with prolonged use

Avoid Interactions

Heminevrin can interact with other medications, altering its safety profile.

Avoid

  • Concomitant use of other central nervous system depressants (e.g., benzodiazepines, opioids, barbiturates, alcohol)
  • Monoamine oxidase inhibitors (MAOIs)
  • Certain antihistamines with sedative properties

Use with caution

  • Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs)
  • Antiepileptic drugs that affect GABA pathways
  • Antihypertensive agents that may enhance hypotensive effects
  • Strong CYP450 inhibitors that could increase clomethiazole levels
  • Herbal supplements such as kava or valerian that have sedative actions

Frequently Asked Questions

Heminevrin contains clomethiazole edisylate as its sole active pharmaceutical ingredient.

The medication is most frequently used to manage alcohol withdrawal syndrome under medical supervision.

It acts as a positive allosteric modulator of the GABA‑A receptor, enhancing the inhibitory effects of GABA and producing sedation.

No. Heminevrin is a prescription‑only product and must be prescribed by a qualified healthcare professional.

Heminevrin is generally intended for short‑term use; prolonged therapy may increase the risk of dependence and should be evaluated by a physician.

Common adverse effects include drowsiness, dizziness, headache, nausea, dry mouth, and mild low blood pressure.

Signs such as severe respiratory depression, profound sedation, marked hypotension, liver dysfunction, allergic rash, or seizures should prompt urgent medical evaluation.

Abrupt discontinuation is not recommended because it may lead to withdrawal symptoms; tapering should be guided by a clinician.

Alcohol should be avoided, as it can potentiate the sedative effects of Heminevrin and increase the risk of respiratory depression.

Other central nervous system depressants, MAO inhibitors, and certain antihistamines should be avoided due to additive sedation.

The safety of Heminevrin during pregnancy or lactation has not been established; it should be used only if the potential benefit justifies the potential risk.

Heminevrin is assigned the ATC code N05CD02, indicating its place in the sedative‑hypnotic category.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Clomethiazole Edisilate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT